Effectiveness of levofloxacin (Eleflox) use in combined therapy for patients with chronic bacterial prostatitis

Cover Page

Cite item

Full Text

Abstract

Objective - to evaluate clinical effectiveness of step-down and peroral therapy with levofloxacin in combined therapy for patients with bacterial prostatitis and comorbid gastrointestinal pathology. Study design - a simple open comparative retrospective non-randomized study. Materials and methods. The study included 116 patients with chronic bacterial prostatitis who attended “Andromed” clinic in the period fr om 2014 to 2017 years. For quantitative symptoms evaluation in assessment and for treatment effectiveness evaluation a questionnaire “Chronic prostatitis symptoms index” developed by National Institute of Health, USA was used. Safety was assessed on the basis of fixed adverse events. All patients received levofloxacin for 28 days: patients in step-down therapy group received levofloxacin 500 mg/d intravenously for 10-12 days with subsequent transition to peroral administration of 500 mg/d, Another group received levofloxacin 500 mg/d in peroral therapy for 28 days. Patients in both groups received adjunctive therapy and physiotherapy in accordance with existing guidelines. All study participants were examined a month after antibiotic therapy was finished. Results. According to clinical examination results no significant differences between two groups were found. Levofloxacin course resulted in pathogen eradication in 82% patients in step-down therapy group and in 81% patients in peroral therapy group wh ere patients received levofloxacin for 28 days. In none of the cases significant adverse events were observed in step-down and peroral therapy with levofloxacin. Conclusion. Levofloxacin is effective in patients with chronic bacterial prostatitis. It is reasonable to use step-down therapy in patients with comorbid gastrointestinal pathology.

About the authors

E. S Dendeberov

Family Medicine Clinic "Andromed"

Email: andromed03@mail.ru
д-р мед. наук, проф. 117449, Russian Federation, Moscow, ul. Vinokurova, d. 2

References

  1. Практическая урология. Под ред. П.В.Глыбочко, Ю.Г.Аляева. М.: Медфорум, 2012.
  2. Аполихин О.И., Абдуллин И.И., Сивков A.B. и др. Хронический простатит. Пленум правления Российского общества урологов. Материалы. М., 2004; с. 5-12.
  3. Деревянко И.И. Бактериальный простатит: этиология, клиника, лечение. Consilium Medicum. 2004; 6 (7): 497-9.
  4. Лопаткин Н.А., Сивков А.В., Аполихин О.И. и др. Хронический простатит. Монография на CD-ROM. М.: НИИ урологии МЗ РФ, 2004.
  5. Пушкарь Д.Ю., Сегал А.С. Хронический абактериальный простатит: современное понимание проблемы. Consilium Medicum. 2003; 7: 401-4.
  6. Трухан Д.И., Филимонов С.Н., Тарасова Л.В. Клиника, диагностика и лечение основных заболеваний почек и мочевых путей. Учебное пособие. Новокузнецк: Полиграфист, 2014.
  7. Щеплев П.А., Кузнецкий Ю.Я. Хронический простатит/синдром хронической тазовой боли. Андрология и генитальная хирургия. 2004; 1-2: 23-30.
  8. Трухан Д.И., Викторова И.А. Болезни почек и мочевых путей. М.: Практическая медицина, 2011.
  9. Пушкарь Д.Ю., Раснер П.И. Простатит. Рус. мед. журн. 2013; 18: 14.
  10. Skerk V, Roglic S, Cajic V et al. Comparison of clinical symptoms scored according to the National Institutes of Health chronic prostatitis symptoms index and assessment of antimicrobial treatment in patients with chronic prostatitis syndrome. J Chermother 2009; 21 (2): 181-7.
  11. Irajian G, Sharifi M, Mirkalantari S et al. Molecular Detection of Ureaplasma urealyticum from Prostate Tissues using PCR-RFLP, Tehran, Iran. Iran J Pathol 2016; 11 (2): 138-43.
  12. Skerk V, Cajić V, Markovinović L et al. Etiology of chronic prostatitis syndrome in patients treated at the university hospital for infectious diseases "Dr. Fran Mihaljević" from 2003 to 2005. Coll Antropol 2006; 2: 145-9.
  13. Choi Y.S, Kim K.S, Choi S.W et al. Microbiological etiology of bacterial prostatitis in general hospital and primary care clinic in Korea. Prostate Int 2013; 1 (3): 133-8.
  14. Hai-Ping Lin, Huo-Xiang Lu. Analysis of detection and antimicrobial resistance of pathogens in prostatic secretion from 1186 infertile men with chronic prostatitis. Nat J Androl 2007; 13 (7): 628-31.
  15. Мацеи T. Индивидуализация применения антибиотиков в отделениях реанимации и интенсивной терапии. Клиническая лекция. Клин. микробиология и антимикробная химиотерапия. 2002; 3 (4): 288-93
  16. Thomas A. Prostatitis. J Royal Soc Med 1981; 74.
  17. Рациональная фармакотерапия заболеваний кожи и инфекций, передаваемых половым путем. Руководство для врачей. Под ред. А.А.Кубановой, В.И.Кисиной. М.: Литтерра, 2005.
  18. Weidner W, Diemer T, Huwe P et al. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents 2002; 19 (6): 466-70.
  19. Bulitta J, Kinzig-Schippers M, Naber C et al. Limitations in the use of drug cocktails to compare the pharmacokinetics of drugs: ciprofloxacin versus levofloxacin. 40th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), Toronto, Canada, 17-20 September 2000 (poster no. 506).
  20. Mihaescu G, Chifiriuc C, Ditu L. Microbiologie Generala. University din Bucuresti: Bucuresti, Romane. 2007.
  21. Reid G, Habash M, Vachon D et al. Oral fluroqunolone therapy results in drug absorbtion on uteral stents and prevention od biofilm formation. Int J Antimicrob Agents 2001; 17 (4): 317-9.
  22. Abdelhamid A.G et al., Cell free preparations of probiotics exerted antibacterial and antibiofilm activities against multidrug resistant E. coli, Saudi Pharm J. 2018 Jul;26(5):603-7. doi: 10.1016/j.jsps.2018.03.004. Epub 2018 Mar 12.
  23. Paglia M, Peterson J, Fisher A et al. Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. Curr Med Res Opin 2010; 26 (6): 1433-41.
  24. Цюман Ю.П. Сравнительный анализ оригинальных и генерических антибиотиков для парентерального применения, используемых в Российской Федерации. Дис. … канд. биол. наук. 2012.
  25. Bjerklund T, Grunberg R, Guibert J et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1988; 34 (6): 457-66.
  26. Naber K, Roscher K, Botto H et al. Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents 2008; 32 (2): 145-53.
  27. Nickel J.С. Chronic prostatitis: an infectious disease? www.medscape.com/viewarticle/410204_1
  28. Choi Y.S, Kim K.S, Choi S.W et al. Microbiological etiology of bacterial prostatitits in general hospital and primary care clininc in Korea. Prostate Int 2013; 1 (3): 133-8.
  29. Studies on men’s health and fertility. Ed. by A.Agarwal, R.Aitken, J.Alvarez. New York: Human Press, LLC, 2012; p. 564-6.
  30. Nickel J.C. Prostatitis. Can Urol Assoc J 2011; 5 (5): 306-15.
  31. Божедомов В.А. Хронический простатит: новая парадигма лечения. Урология. 2016; 3 (Прил.): 78-90.
  32. Пушкарь Д.Ю., А.В. Зайцев А.В., Раснер П.И. Оптимизация алгоритма диагностики и лечения хронического бактериального простатита. РМЖ. 2008; 16 (17): 1134-8.
  33. Аляев Ю.Г., Шпоть Е.В., Султанова Е.А. Применение левофлоксацина (Лефокцина) при хроническом простатите. РМЖ. 2011; 19 (16): 1018-23.
  34. Белоусов Ю.Б., Мухина М.А. Клиническая фармакология левофлоксаина. РМЖ. 2002; 23: 1057-62.
  35. Drusano G.L, Preston S.L, Van Guilder M et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44 (8): 2046-51.
  36. Croom K.F, Goa K.L. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63 (24): 2769-802.
  37. Garcia-Castillo M, Morosini M, Galvez M et al. Differences in biofilm development and antibiotic susceptibility among clinical Ureaplasma urealyticum and Ureaplasma parvum isolates. J Antimicrob Chemother 2008; 62 (5): 1027-30.
  38. Heras-Caсas V, Gutierrez-Soto B, Almonte-Fernandez H et al. Antibiotic activity and concentrations in clinical samples from patients with chronic bacterial prostatitis. Actas Urol Esp 2017; 41 (10): 631-8.
  39. Meliegy E, Torky M. An observational study to monitor the efficacy and tolerability of levofloxacin 500 mg once daily for treatment of chronic bacterial prostatitis in Saudi Arabia. Urol Ann 2015; 7 (1): 71-3.
  40. Schaeffer A.J, Anderson R.U, Krieger J.N et al. The assessment and management of male pelvic pain syndrome, including prostatitis. https://www.scholars.northwestern.edu/en/ publications/the-assessment-and-management-of-male-pelvic-pain-syndrome-includ-3
  41. Wagenlehner F, Naber K, Bschleipfer T et al. Prostatitis and Male Pelvic Pain Syndrome Diagnosis and Treatment. Dtsch Arztebl Int 2009; 106 (11): 175-83.
  42. Nickel J, Downey J, Feliciano A et al. Repetitive prostatic massage therapy for chronic refractory prostatitis: the Philippine experience. Tech Urol 1999; 5 (3): 146-51.
  43. Nickel J, Downey J, Clark J et al. Antibiotic pharmacokinetics in the inflamed prostate. J Urol 1995; 153 (2): 527-9.
  44. Nelson W.G, De Marzo A.M, DeWeese T.L, Isaacs W.B. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: 6-11.
  45. Vicari L, Castiglione R, Salemi M et al. Effect of levofloxacin treatment on semen hyperviscosity in chronic bacterial prostatitis patients. Andrologia 2016; 48 (4): 380-8.
  46. Weidner W, Wagenlehner F, Marconi M et al. Acute bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: andrological implications. Andrologia 2008; 40 (2): 105-12.
  47. Инструкция по применению левофлоксацина П№016110/01-051216.
  48. Bergman B. On the relevance of gram-positive bacteria in prostatitis. Infection 1994; 22 (l): 22.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies